ß-amyloid cyclic ribonucleic acid, polypeptide, and application thereof
OwnerDingding Moinventor
Life of this patent
Estimating the term…
Abstract
The invention discloses a β-amyloid cyclic ribonucleic acid, a polypeptide and an application thereof. The present invention finds that the APP gene can generate a variety of circular RNAs from the Aβ coding region through reverse splicing, which is named β-amyloid circular ribonucleic acid circAβ. With the help of the newly established circular RNA research method, a variety of peptides produced by circAβ were identified, and such peptides could be further processed to form Aβ, which in turn formed β-amyloid plaques in primary neuronal cultures, reflecting key hallmarks of AD neuropathology. circAβ and its translated proteins represent novel targets in AD therapy.
Claims2
An antisense oligonucleotide, comprising an oligonucleotide that is synthetic and chemically-modified, having one or more chemical modifications selected from the group consisting of phosphorothioate, 2′-O-methyl, 2′-O-(2-methoxyethyl), locked nucleic acid (LNA), morpholino, and peptide nucleic acid (PNA), complementary to and capable of hybridizing with a target sequence, wherein the target sequence comprises a sequence of a β-amyloid cyclic ribonucleic acid (circAβ), the circAβ comprising a back-splice junction (BSJ) region and a base sequence of at least one exon of the transmembrane amyloid precursor protein (APP) gene or a partial sequence thereof, or a sequence that is substantially homologous to the sequence and derived from the same species,
- wherein the circAβ is capable of expressing or producing Aβ40 or Aβ42, or fragments thereof, and comprises at least one sequence selected from the group consisting of SEQ ID NOS:
- 1-17, and
- wherein the antisense oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NOS:
- 41-57 and hybridizes under stringent conditions to circAβ but not detectably to linear APP mRNA.
Dependencies are inferred from the claim text.